Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer
This is a single-center, open phase II clinical trial to evaluate the tolerability, safety and efficacy of toriparib monotherapy in the treatment of locally advanced dMMR/MSI-H gastric or gastroesophageal junction adenocarcinoma.
Gastric or Gastroesophageal Junction Adenocarcinoma
DRUG: PD-1 inhibitor
Pathological complete remission (pCR) rates, Percentage of patients who achieve pathological complete remission (pCR), 12 weeks
R0 resection rates, The proportion of patients experiencing a R0 resection, 12 weeks|three-year disease-free survival rate, DFS, Percentage of patients who achieve disease-free survival lasting for more than three years, 3 years|three-year Overall survival rate,OS, Percentage of patients who achieve survival for more than two years, 3 years|Incidence of Treatment-Related Adverse Events, Number of adverse events., 3 years
In this phase II study, eligible patients are enrolled to receive toripalimab 240mg, ivdrip, Q3W to evaluate the anti-tumor efficacy and safety. After 2 and 4 cycles of toripalimab treatment, tumors are assessed, and patients are assigned to receive surgery or withdraw from study according to their anti-tumor efficacy. For patients withdrawing from study, routine treatment would be given. For patients staying in study, toripalimab would be administered for up to 2 years.